Addus HomeCare Corp has a consensus price target of $98.5, established from looking at the 35 latest analyst ratings. The last 3 analyst ratings were released from TD Cowen, Stephens & Co., and B of A Securities on May 9, 2024, May 7, 2024, and May 7, 2024. With an average price target of $117.33 between TD Cowen, Stephens & Co., and B of A Securities, there's an implied 10.59% upside for Addus HomeCare Corp from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|
The latest price target for Addus HomeCare (NASDAQ: ADUS) was reported by TD Cowen on May 9, 2024. The analyst firm set a price target for $119.00 expecting ADUS to rise to within 12 months (a possible 12.16% upside). 18 analyst firms have reported ratings in the last year.
The latest analyst rating for Addus HomeCare (NASDAQ: ADUS) was provided by TD Cowen, and Addus HomeCare maintained their buy rating.
There is no last upgrade for Addus HomeCare.
The last downgrade for Addus HomeCare Corp happened on April 23, 2024 when Barclays changed their price target from N/A to $83 for Addus HomeCare Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addus HomeCare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addus HomeCare was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.
While ratings are subjective and will change, the latest Addus HomeCare (ADUS) rating was a maintained with a price target of $105.00 to $119.00. The current price Addus HomeCare (ADUS) is trading at is $106.10, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.